4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
TransThera Sciences (Nanjing), Inc. (2617) operates in the Biotechnology industry and is headquartered in Nanjing, China with about 123 employees. Its market capitalization is roughly CNY 5 billion. In the fiscal year ended 2025-12-31, 2617 reported CNY 0M in revenue and (CNY 296M) in net income.
TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Revenue | CNY 0M | CNY 0M | CNY 1M |
| Gross Profit | CNY 0M | CNY 0M | CNY 1M |
| Operating Income (EBIT) | (CNY 300M) | (CNY 287M) | (CNY 372M) |
| Net Income | (CNY 296M) | (CNY 275M) | (CNY 343M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Assets | CNY 546M | CNY 630M | CNY 887M |
| Total Liabilities | CNY 130M | CNY 105M | CNY 104M |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2617 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms